Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study.

Sara M TolaneyKevin KalinskyVirginia G KaklamaniDavid R D'AdamoGursel AktanMichaela L TsaiRuth M O'ReganPeter A KaufmanSharon T WilksEleni AndreopoulouDebra A PattYuan YuanGrace WangClaudio SavulskyDongyuan XingElla KleynermanVassiliki KarantzaSami Diab

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Eribulin plus pembrolizumab was generally well tolerated and showed promising antitumor activity in mTNBC. Efficacy outcomes appeared influenced by line of therapy and PD-L1 status.

Keyphrases

metastatic breast cancer
advanced non small cell lung cancer
phase ii
stem cells
type diabetes
clinical trial
mesenchymal stem cells
metabolic syndrome
weight loss